- Phlow Corp. and Antheia have partnered to onshore the production of essential medicine components in the U.S.
- The collaboration focuses on using biosynthesis and flow chemistry to produce key starting materials and APIs domestically.
Phlow Corp., a pharmaceutical CDMO based in the United States, has announced an ongoing partnership with Antheia to domestically manufacture essential medicine components. The collaboration aims to establish a more resilient and efficient pharmaceutical supply chain through the onshoring of key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
The partnership began in 2024 and leverages Antheia’s biosynthesis platform to support Phlow’s flow chemistry-based manufacturing of essential medicines. This initiative seeks to reduce reliance on imported pharmaceutical components, nearly 80% of which are currently sourced from outside the U.S.
“This partnership with Antheia marks a major milestone in reshoring and securing the domestic supply chain for essential and life-changing medicines,” said Eric S. Edwards, M.D., Ph.D., CEO and Chairman of Phlow. “By working together to develop a U.S.-based, sustainable alternative for key starting materials derived from unpredictable, legacy sources, we are not only protecting American patients, but we’re also advancing our shared mission to strengthen national health security.”
The companies emphasise that their integrated approach—combining biosynthesis, biomanufacturing, and continuous flow chemistry—provides an end-to-end solution for U.S.-based production of critical drugs. This aligns with national efforts to combat drug shortages and enhance public health preparedness.
